UCB reports 7% increase in sales for 2014

Published: 3-Mar-2015
Finance

Three drugs now account for 50% of net sales


UCB reported a 7% increase in sales to €3.3bn in 2014.

The Belgian company saw continued growth with anti-inflammatory Cimzia, epilepsy drug Vimpat and the Neupro patch for Parkinson's and restless legs syndrome, which now account for 50% of net sales at €1.5bn.

Turnover for anti-epileptic drug Keppra fell 7% to €655m.

Chief Executive Jean-Christophe Tellier said the company was preparing to launch its next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab and was excited about the progress in its early pipeline.

Other revenue in 2014 increased to €243m, mainly due to the payments from partners, Sanofi and the European Investment Bank (EIB).

Gross profit rose to €2.3bn (+6%), while recurring EBITDA was up 14% to €609m.

Looking forward, UCB expects the continued growth of Cimzia, Vimpat and Neupro to drive overall company growth. 2015 revenue should reach approximately €3.55–€3.65bn, while recurring EBITDA should increase to €710–€740m.

  • Companies:
  • UCB
See more

You may also like

Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Read more
Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Lannett to acquire Kremers Urban Pharmaceuticals for US$1.23bn

Lannett believes the acquisition will substantially increase and diversify its revenue base with profitable specialty products
Finance

Dr Reddy’s to buy allergies and respiratory franchises in India from UCB for €118m

Strengthens its presence in dermatology, respiratory and paediatrics medicines
Manufacturing

CPI-led UK biotech consortium secures £6.2m of government investment

Project aims to reduce the time it takes to bring biologics to market
Finance

Manufacturers to get more support from UK government

The UK government has announced the latest winners from a fund to help rebuild British manufacturing prowess
Finance

UCB pulls out of deal to sell Kremers Urban

Cites conflicting timing for the acquisition including its financing and the regulatory process
Finance

UCB to sell Kremers Urban to private equity for US$1.53bn

Belgian company will focus on its core business in neurology and immunology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Fostering the development of innovative medicines

Confidence in the pharma sector seems to be picking up, with higher drug approvals in the US, M&A activity increasing and opportunities in emerging markets. However, healthcare reforms and pricing pressures are driving the industry to improve productivity and gain a better knowledge of disease mechanisms at the molecular level. Data sharing and collaborative projects seem to be the way forward
Subscribe now